drugset / Trial / NCT04606537
Drug to Drug Interaction Study of KBP-5074 in Healthy Subjects
Non-randomizedParallel-groupOpen-labelBasic science
Summary
Open-label, parallel, 2-arm, fixed-sequence study to investigate the effect of coadministration of a CYP3A4 inhibitor (Cohort 1, itraconazole multiple dose) and CYP3A4 inducer (Cohort 2, rifampin multiple dose) on the plasma PK of a single dose of KBP-5074 in healthy male and female subjects.
Timeline
- Start
- 2020-10-24
- Primary completion
- 2020-11-30
- Completion
- 2020-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | Oral |
| Subject | Ocedurenone | Small molecule | 0.5 mg | Oral |
| Subject | Rifampicin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.